Addex Reports Q3 2023 Financial Results and Provides Corporate Update
November 29, 2023 01:00 ET
|
Addex Therapeutics
ADX71149 Phase 2 epilepsy clinical study completes recruitment of patients, with top line results expected in Q2 2024mGlu2 NAM cognition program receives a €4 million Eurostars grantCHF 4.8M ($5.2M)...
Addex Convenes Extraordinary General Meeting
November 28, 2023 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 28, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023
November 23, 2023 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, November 23, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...
Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
November 14, 2023 01:00 ET
|
Addex Therapeutics
Top line results expected in Q2 2024 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 14, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage...
Addex Regains Nasdaq Listing Compliance
November 08, 2023 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 8, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex Announces Participation in the Bio-Europe 2023 Conference
November 02, 2023 02:00 ET
|
Addex Therapeutics
Geneva, Switzerland, November 2, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...
Addex Completes ADS Ratio Change
October 20, 2023 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 20, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex Announces Plan to Implement ADS Ratio Change
October 06, 2023 16:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 6, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex mGlu2 NAM Cognition Program Receives €4 Million Grant
September 20, 2023 01:00 ET
|
Addex Therapeutics
Addex led consortium wins Eurostars grant to deliver clinical candidates to treat mild neurocognitive disorders Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 20, 2023 -...
Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, September 6, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...